Cancer patients with Down syndrome (DS) are prone to anthracyclines related cardiotoxicity, which could be explained by increased expression of CBR1 and increased metabolism of daunorubicin to the ethanol metabolites in the heart (34). Here, CBR1 is linked to Dravet syndrome.